$CFRX
Their drug is called Exebacase, it’s in Phase 3 testing for MRSA antibiotic-resistant bacteria.
The drug failed to meet its primary endpoint in Phase 2 for MRSA and MSSA related bacterias, but Phase 3 target readjusted to focus on MRSA only. Thus, there’s a very high chance of success.
If successful, it would be the first and only treatment of its kind. Stock is currently valued at 150M. Approved, I think it should be worth 1.5B. If it fails, we pretty much lose all our money.
I like the risk to reward.
Leave a Reply